Status:
UNKNOWN
ADAPT Transcatheter Aortic Valve Intervention (TAVI & Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI)
Lead Sponsor:
Erasmus Medical Center
Collaborating Sponsors:
Roche Diagnostics GmbH
Conditions:
Transcatheter Aortic Valve Replacement
Percutaneous Coronary Intervention
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Rationale: The choice of antithrombotic regimen during TAVI and CTO PCI includes the use of unfractionated heparin. The accuracy of ACT in this setting is disputed. ACT has never been compared to a po...
Detailed Description
The choice of antithrombotic regimen during TAVI and CTO PCI includes the use of unfractionated heparin. Heparin is the preferred anticoagulant drug in these percutaneous cardiac interventions aiming ...
Eligibility Criteria
Inclusion
- All patients undergoing a TAVI-procedure
- All patients undergoing a CTO PCI procedure
Exclusion
- none
Key Trial Info
Start Date :
October 20 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2023
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT05259241
Start Date
October 20 2020
End Date
January 1 2023
Last Update
July 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Erasmus University Medical Center
Rotterdam, South Holland, Netherlands, 3015GD